Healthy Clinical Trial
Official title:
Drug Interactions and Bioavailability of Cranberry
The purpose of this study is to evaluate the potential of cranberry juice to interact with conventional drugs. This study will also determine the the amount of cranberry flavonoids that appear in the blood and in the urine.
The use of cranberry (CB) juice and powders, both alone and in combination with conventional
medicine, has become more common for the treatment of urinary tract infections (UTIs) and and
other acute or chronic conditions. Cytochromes P450 enzymes are a group of proteins involved
in metabolism of certain substances. A group of cytochrome P-450 (CYP) enzymes are
extensively involved in drug metabolism. The pharmacokinetics of many drugs often vary
considerably among individuals, largely because of variations in the expression of different
cytochrome P-450 (CYP) enzymes in the liver and other tissues. Flavonoids are antioxidants
that may have health benefits. The flavonoids may also be responsible for cranberry's effects
on urinary tract infections.
To evaluate the drug interaction potential of cranberry, single doses of the three safe probe
drugs alprazolam, dextromethorphan, and caffeine will be administered before and after a
14-day treatment period with cranberry powder. Changes in the pharmacokinetics of these probe
drugs will indicate the degree of enzyme inhibition or induction. The key pharmacokinetic
parameters for four major CB flavonoids will be estimated by following the plasma
concentration versus time course of absorbed flavonoids and their excretion in urine. The
area under the plasma concentration versus time curve (AUC), oral clearance (Clo), terminal
elimination half-life (T1/2) and renal clearance (Clren) will be determined for: epicatechin,
quercetin (total glycosides), procyanidin A2, and cyanidin-3-galactoside.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |